

Index

- 1-800-DENTIST, 396
 23andMe, 536
 3rd Stone Design, 492–4
 510(k)
 abbreviated, 327
 clinical data for, 541
 cost, 331
 de novo clearance, 326
 meeting with FDA, 541
 predicate device, 325, 538
 review process and timing, 327
 special, 327
 strategies, 538
 submission, 327
 substantial equivalence, 325, 538
- Abbott Vascular, 471, 679
 Abele, John, 183, 635
 acceptance criteria, 51, 54–9, 219, 276
 AccessClosure, 646–8
 Acclarent, 105–9, 239–45, 251, 280–1, 375, 449–54, 686–98, 809–16
 accountable care organizations, 158, 194, 359, 396, 398, 585, 636
 Accuray, Inc., 618, 629–33, 649–51
 Ackermann, Michael, 412–13, 486–9
 acquisition, 732, 754–5
 Acumen Fund, 762
 Adler, John, 629–33, 649–51
 Advanced Cardiovascular Systems (ACS), 442, 803
 Advanced Medical Technology Association (AdvaMed), 627, 649
 advocacy, 161, 595–6, 623, 649
 Affordable Care Act, 158, 351, 359, 585, 616, 652
 Africa, 10–12, 173–6, 384–7
 AirCare, 86
 Alamin, Todd, 438, 441–2, 737–9
 AliveCor, 396
 Allen, Michael, 361–2
 alternate pathways
 acquisition, 793–5
 building value toward, 797–800
 build-to-buy, 794
 lack of market access, 787
 licensing, 788–9, 805–6
 managing, 801–2
 partnering, 789–93
 preparing for, 800
 returns, timing, and cost issues, 787–8
 sale, 793–5
 America Invents Act, 288, 472
 America Society of Quality (ASQ), 553
 American Medical Association (AMA)
 code of ethics, 65
 CPT codes, 353–5
 Relative Value Scale Update Committee, 583
 American Medical Systems (AMS), 55, 671
 anatomy, 119–20
 Angiotech, 666
 animal studies, 507–9
 Anner, John, 209
 Aravind Eye Hospital, 85
 Ardian, 126–30
 ArthroCare Corporation, 484, 496
 AstraZeneca, 789
 athenahealth, 627
 Atritech, 146
 Australia, 336–7, 688–90
 Azagury, Dan, 729
- Bakan, Greg, 531
 Bakken, Earl, 53
 barrier to entry, 458, 541, 645, 665, 669
 Bartlett, Rush, 420–3
 BATNA, 800–1
 Baxter, 673
 Beasley, Bill, 466
 Beggins, Scott, 341–4
 bench testing, 423–4, 491
 Bennett, Ian, 438–9, 737–9
 Bill & Melinda Gates Foundation, 758, 793
 BioInnovate, 87
 Biosense Technologies, 333
 Biosensors, 460
 BioTrace Medical, Inc., 771
 Blue Cross Blue Shield, 157, 358, 588
 Blue Cross Blue Shield Technology Evaluation Center (TEC), 360, 581, 589
 Boston Scientific, 552–3, 582–3, 640, 670, 679
 brainstorming
 alternate approaches, 262–6
 capturing ideas, 256, 261–2
 choosing a facilitator, 258–9
 framing the question, 252–3
 ‘how might we’ questions, 252–3
 IP ownership, 262
 managing the session, 260–1
 preparing for, 800
 rules, 253–6
 selecting participants, 257–8
 use of artifacts, 255, 259
 Brazil, 32–5, 338
 bridge loan, 752
 Bruzzi, Mark, 87–8
 business model, 373
 choosing, 374–6
 defining characteristics, 374
 factors affecting, 374
 operationalizing, 400–1
 validating, 400
 business model types
 capital equipment, 383–4
 disposable, 376–8
 fee per use, 391
 implantable, 380–1
 over-the-counter, 394
 physician-sell, 395
 prescription, 394–5
 reusable, 380
 service, 387–8
 subscription, 393–4
 business plan, 726–7
 business planning
 executive summary, 734–7
 importance of the team, 744–5
 intrapreneurship, 745–6
 business strategies
 disease management, 673–4
 distribution play, 673
 fast follower, 669–70
 first mover, 669
 information aggregator, 675
 low-cost provider, 671–2
 me-too, 670
 niche play, 670–1
 OEM/licensing, 678
 overview, 669
 partnering, 678–9
 Buxbaum, Darin, 262–3

Index

- C.R. Bard Inc., 562, 623
 Cahill, Colin, 438, 737–9
 Callaghan, Matt, 445–7
 Cambridge Antibody Technology, 789
 Cardica, Inc., 637, 705, 710–14
 Cardiocom, 397–400
 Caro, Elias, 758–61
 Carusi, Mike, 531, 546
 Casciaro, Gregory, 646–9, 651
 cash flow statement, 720–1
 cash requirements, 721, 740, 749, 773
 CE mark, 334–6, 547–8, 703
 Center for Biologics Evaluation & Research (CBER), 321, 536
 Center for Devices & Radiological Health (CDRH), 321, 323, 536–7, 580
 Center for Drug Evaluation & Research (CDER), 321, 536
 Centers for Medicare and Medicaid Services (CMS), 86, 157, 168, 320, 351, 506, 535, 574
 certificate of conformity, 335, 338
 Chang, John, 105–9, 239–45, 280–1, 449–54, 686–98, 809–16
 Chasmawala, Nish, 210–13
 Chaturvedi, Jagdish, 229
 Chehab, Eric, 236–8
 Chin, Albert, 795
 China, 14–17, 156, 159, 172, 304–5, 339–40, 367–8, 460, 672–3
 Ciel Medical, 729
 Cierra, Inc., 229–33
 Cigna, 581
 Circ Medtech, 762
 clinical studies
 case control, 510–11
 costs, 520–1
 ethics, 522–3
 first-in-human, 337, 509–10, 521
 GCP, 522
 geographic location, 521–2
 GLP, 509–10
 IACUC, 508
 pre-clinical, 507–8
 randomized, controlled, 511–12
 registries, 510
 trial nomenclature, 512
 clinical study goals
 marketing, 507
 regulatory, 506
 reimbursement, 506
 clinical trial design
 endpoints, 167, 513, 523
 hypothesis, 512
 IDE, 514–15, 537
 informed consent, 517–18
 investigators and center, 514
 IRB, 515
 patient enrollment, 516–17
 size, 513
 statistical design, 511–12
 statistical power, 513–14
 tips, 523
 clinical trial management
 data management, 520
 research site staff, 519
 sponsor personnel, 519
 coding, *see* reimbursement in the US
 common stock, 751
 comparables analysis, 619, 723, 774
 competitive advantage
 basis of competition, 679
 capabilities, 664, 667–9
 link to value proposition, 665
 positional, 664–7
 statement of, 682
 Computer Motion, 474–6
 Concentric Medical, 378–80
 concept map, 270, 272–4
 concept screening
 clustering, 270–2
 concept mapping, 272–4
 eliminating ideas, 274–6
 involving experts, 275–6
 killer risks, 315–16, 344–5, 369–70, 401, 433
 organizing ideas, 270–4
 transition from ideation, 269–70
 concept selection, 433
 alternatives to Pugh method, 441–2
 getting to leading concepts, 434–5
 Pugh method, 436–41
 taking a structured approach, 435–6
 conflict of interest, 62, 465, 514–15, 522–3, 622, 802
 conformity assessment, 335
 Conor Medsystems, 771–3
 Consure Medical, 210–13
 contract research organization (CRO), 514
 contracting administration fee (CAF), 652
 copyright, 287
 Corbett, Jim, 680–2
 Cordis, *see* Johnson & Johnson
 core laboratories, 518
 CoreValve, 306–8
 Coridea, 56, 756
 cost-effectiveness, 147, 167, 367, 506, 589–90
 cost of goods sold (COGS), 703, 715
 cost projections
 manufacturing costs, 715–17
 operating expenses, 717–19
 salary analysis, 715
 Coulter Foundation, 758–61
 Cowling, Don, 674–5
 Croce, Bob, 115–17
 Curtis, Gary, 378–80
 Cyberonics, 580
 cycle of care analysis, 69, 153–6, 605
 Cycle Technologies, 621
 Daktari Diagnostics, 173–6
 Dambkowski, Carl, 236–8
 data entry and monitoring, 518
 data safety and monitoring board, 519
 Davila, Liz, 391–3
 debt funding, 751
 Deem, Mark, 126–30, 136–7, 229–33, 265, 434
 depreciation, 720
 design controls, 556
 design validation, 556
 design verification, 556
 Devices for Vascular Intervention (DVI), 523–6
 Disonics, 568–71
 digital health, *see* mobile health
 dilution, 771–2, 777
 direct sales models
 interaction with marketing, 649
 role of payers, 648
 sales training, 648–9
 selling process, 643–5
 discount rate, 774
 discounting terminal value, 774
 disease function, *see* mechanism of action
 disease progression, 121–2
 disease state research
 anatomy, 119–21
 clinical outcomes, 123–4
 clinical presentation, 122–3
 economic impact, 124
 epidemiology, 118–19
 optimizing, 124–6
 pathophysiology, 121–2
 physiology, 119–21
 summarizing, 126
 Dollens, Ron, 627
 Donaldson, Krista, 209–10
 D-Rev, 88, 375–6, 758
 due diligence, 767–8, 800
 earnings statement, *see* income statement
 East Meets West Foundation, 209
 Edwards Lifesciences, 341–4

- Ehrenreich, Kevin, 565–7
elevator pitch, 729
Embrace, 758, 762
empathy, 61, 72, 125
Emphasys Medical, 136–7, 527–30, 544–7
Endogastric Solutions, 666
Engelson, Eric, 229–33
engineering, *see* R&D
epidemiology, 118
equity funding, 750, 793
equity vs. debt, 750–1
Ethicon, 668
ethics
 AdvaMed code of ethics, 627, 649
 AMA code of ethics, 65
 conflict of interest, 62, 465, 514–15, 522–3, 622, 802
 fiduciary duty, 63
 IACUC, 508
 in marketing, 627
 in observations, 76–7
 informed consent, 517–18
 overview, 62–5
 principles, 64–5
 stakeholder analysis, 178–9
 Tuskegee syphilis experiment, 63
ethnographic research, 72
Europe, 18–21, 87–8, 303, 306–8, 334–6, 341–4, 364–7, 547–9, 674–5
European Patent Office (EPO), 303
ev3, 679–82
Evalve, Inc., 426–9
evergreening, 471
exclusion criteria, 517
exempt devices, 323–5
exit event, *see* liquidity event
ExploraMed, 56, 59–61, 106, 756
EyeNetra, 762
Facteau, William, 449–54, 686–98, 809–15
Fahey, Brian, 423
Farley, Brian, 597–601
Federal Food and Drugs Act, 320
Fielding, Louie, 438, 737–9
financial model
 cash balance and financing needs, 721
 cash flows, 720–2
 cost projections, 715–19
 income statement, 719–20
 market model, 707–10
 operating plan, 705
 overview, 703–4
 profitability, 722
 staffing plan, 705–7
 financing milestones, 722, 768–71
 first-in-human testing, 337, 509–10, 521
FitBit, 396
flow of money analysis, 153, 156–8, 605
Fogarty, Thomas, 77, 251, 351, 457, 703
Food & Drug Administration (FDA)
 background, 319–21
 clinical data from outside the US, 340–1
 definition of medical device, 321
 device classification, 321–3
 fees, 330
 GCP, 522
 GLP, 509–10
 GMP, 562
 HDE, 330
 IDE, 329–30
 MFUFMA, 330
 mobile health, 331–4, 536
 QSR, 325, 552
 regulatory pathways, 323–9
Food, Drug, and Cosmetic Act, 320
Foundry, The, 56, 126–30, 136–7, 229–33, 265, 434, 527, 546, 756
Fox Hollow, 667
France, 19, 365–6
freedom to operate, 289, 461–2
Frenkel, Erica, 384–7
From the Field
 AccessClosure, 646–8
 Accuray, Inc., 629–33, 649–51
 ACS, 442
 Ardian, 126–30
 ArthroCare Corporation, 484
 Cardica, Inc., 710–14
 Cardiocom, 397–400
 Cierra, Inc., 229–33
 Concentric Medical, 378–80
 Consure Medical, 210–13
 CoreValve, 306–8
 Coulter Foundation, 758–61
 Daktari Diagnostics, 173–6
 Diasonics, 568–71
 DoseRight Syringe Clip, 492–4
 DVI, 523–6
 Edwards Lifesciences, 341–4
 Emphasys Medical, 136–7, 527–30, 544–7
 ev3, 679–82
 Evalve, Inc., 426–9
 ExploraMed, 59–61
 Genomic Health, 206–9, 619–20
 Gradian Health Systems, 384–7
 HiCARE LIMO, 82–3
 InnerPulse, 169–72
 Intuitive Surgical, 473–6
 iRhythm, 312–15
 Johnson & Johnson, 115–17
 Kyphon, 657–61
 Loma Vista Medical, 777–81
 Medtronic, 52–3
 Merck Serono, 674–5
 Metrika, Inc., 361–2
 Mindray Medical, 672–3
 Miramar Labs, 606–11
 Nanostim, 790–3
 NeoTract, Inc., 499–502
 Northwestern University, 98–9
 Oculeve, 412–13, 486–9
 OEC Medical Systems, 568–71
 OneBreath, 445–7
 Phoenix Medical Systems, 641–2
 Qualcomm Life, 675–8
 Radiology Partners, 388–91
 Rapid Exchange, 803–5
 Respironics, 79–81
 Simpirica Spine, 737–9
 Singapore-Stanford Biodesign, 277–8
 Spiracur, 463–4, 806–7
 St. Francis Medical, 381–3
 Stanford University team, 236–8, 262–3
 Sympara Medical, 565–7
 The Foundry, 126–30, 136–7, 229–33
 University of Cincinnati, 79–81
 VentureHealth, 763–4
 Versant Ventures, 742–4
 VISX, 391–3
 VNUS Medical, 597–601
 Vortex Medical, 795–7
 Vynca, 420–3
 Wing Tech Inc., 590–4
functional blocks, 404, 413–15
funding
 choosing investors, 767
 dilution, 771
 due diligence, 767–8
 equity vs. debt, 750–1
 exit scenarios, 754–5
 managing the process, 776–7
 milestones, 768–71
 sources, 767
 stages/uses, 753–4
 strategic considerations, 774–5
 term sheet, 775–6
 valuation, 771–5
funding types
 debt, 751
 equity, 750
 grants, 751

Index

- Gantt chart, 489, 731
 Garrett, Kate, 729
 Gelsinger, Jesse, 310, 516
 Genomic Health, 206–9, 619–20
 Germany, 18, 364–5
 GI Dynamics, 666
 Gifford, Hanson, 126–30, 136–7, 229–33, 527–30, 544–7
 Given Imaging, 326
 Glenn, Ben, 314
 Glennon, Mike, 795–7
 Global Harmonization Task Force (GHTF), 334
 Gonzalez, Richard, 793
 Good Clinical Practices (GCP), 522
 Good Laboratory Practices (GLP), 509–10
 Good Manufacturing Practices (GMP), 562
 Gorsky, Alex, 636
 Gradian Health Systems, 384–7
 grant funding, 751
 Green, David, 85
 Green, Eric, 505
 group purchasing organizations (GPO), 639
 Guidant, 164, 621, 628, 669
 Guo, Christine, 388–91
- Hawkins, William, 53
 Health Care Professionals Advisory Committee Review Board (HCPAC), 355
 Health Insurance Portability and Accountability Act (HIPAA), 77
 health maintenance organizations (HMOs), 359
 HealthTap, 396
 HiCARE LIMO, 82–3, 614
 humanitarian device exemption (HDE), 330
- IDEO, 253–4, 260
 Imran, Mir, 94, 727, 749, 763–4
 incidence, 118
 inclusion criteria, 594
 income statement, 719–20
 Independent Payment Advisory Board (IPAB), 585
 India, 23–6, 72, 82–3, 86–7, 156, 159, 161, 173, 210–13, 304, 339, 368–9, 375–6, 641–2
 Indian Patent Office (IPO), 304
 indications for use (IFU), 320, 327, 542
 indirect sales and distribution models
 national distributors, 639
 specialty distributors, 639–40
 third-party partnerships, 640–2
 informed consent, 330, 517–18
 InHealth, 590
 initial public offering (IPO), 732
- InnAccel, 229
 InnerPulse, 169–72, 196–7, 679
 innovation notebook, 74, 308, 467
 Institutional Animal Care and Use Committees (IACUC), 508
 Institutional Review Board (IRB), 329, 515, 537
 integrated delivery network (IDN), 158, 639
 intellectual property (IP), 458
 documentation, 308–9
 freedom to operate, 289, 461–2
 international patenting, 302–6
 inventorship, 309
 law, 464
 patent searching, 289–95
 patentability, 288–9
 prior art, 289–91, 295
 provisional patent, 295–7
 public disclosure, 310–11, 467
 reduction to practice, 289
 utility patent, 297–302
 intellectual property strategy
 defensive, 467–9
 freedom to operate, 461–2
 hiring legal help, 464–5
 international, 465–6
 litigation, 471–2
 managing a patent portfolio, 466–7
 offensive, 469–70
 patent coverage, 459–61
 timing, 470–1
- Intermountain Health, 652
 International Medical Device Regulators Forum (IMDRF), 334
 International Organization for Standardization (ISO), 333, 562
 International Searching Authority (ISA), 302
 intrapreneurship, 723, 745–6
 Intuitive Surgical, 400, 473–6, 540, 622
 investigational device exemption (IDE), 329–30, 514–15
 investors, *see* funding sources
 Invivo Surgical Systems, 640
 Ireland, 8, 87–8, 757
 iRhythm, 312–15
- Jacobs, Jamey, 800
 Jaffe, Ross, 742–4
 Janssen Labs, 756
 Japan, 28–30, 337, 606–11
 Johnson & Johnson, 115–17, 636, 670, 679, 756
 Jones, Don, 675–8
- Kaiser Permanente, 158, 162, 359, 652
 Kamal, Ritu, 86–7
- Kano model analysis, 416–19
 Kelley, Tom, 248, 260, 416
 Kelso, David, 98–9
 key opinion leader (KOL), 95, 506, 595, 617, 627, 769
 Khosla Impact, 762
 Khosravi, Fred, 646
 Knappe, Brett, 397–400
 Kumar, Uday, 312–15
 Kumar, V. Sashi, 641–2
 Kyphon, 548, 657–61, 664, 669, 682–4
- Lake Region Corporation, 678
 Lam Wang, Sharon, 239–45, 449–54, 686–98, 809–16
 Lamson, Ted, 59, 499–502
 Lebeau, Guy, 162, 480
 lexicographer, 461
 licensing, 641, 678, 754
 Lifescan, 640
 Linehan, John, 590, 593
 liquidity event, 732, 766, 769, 771, 826
 local coverage determination (LCD), 353, 578
 Loma Vista Medical, 623, 777–81
 Lu, Yoh-Chie, 460
- Makhzoumi, Mohamad, 388–91
 Makower, Josh, 59–61, 105–9, 239–45, 280–1, 449–54, 686–98, 809–16
 market analysis
 choosing target market, 201–3
 global considerations, 209–10
 landscaping the market, 183–6
 market development, 618
 pitfalls, 205–6
 segmenting the market, 186–201
 market model
 bottom-up, 192, 643, 708–10
 top-down, 191–4, 707–8
 marketing
 communication strategy, 623–7
 market research, 605–6, 611
 public relations strategy, 627–9
 value proposition, 611–18
 marketing mix
 positioning, 622–3
 pricing, 619–22
 product/service mix, 618–19
 promotion, 623–9
 master resellers, 640
 May, Allan, 568–71, 790–3
 McCutcheon, John, 527–30, 544–7
 McGlynn, Casey, 765
 MDStart, 756

- mechanism of action, 100, 146, 235, 272
- Medicaid, 157
- Medical Device Amendments Act, 320
- medical device reporting (MDR), 559
- Medical Devices Directive (MDD), 334
- medical necessity, 167
- Medicare, 85, 157, 165, 351
- Medinol, 640
- Medtronic, 52–3, 129, 306–8, 397–400, 583, 640, 679
- Merck Serono, 674–5
- Metrika, Inc., 361–2, 575
- Mexico, 32–5, 486–9, 504–5
- Mindray Medical, 672–3
- Miramar Labs, 606–11
- Miros, Robert, 492–4
- mission statement, 51–4
- mobile health, 134, 163, 202, 331–4, 395–7, 536, 704
- Mobile Medic, 758
- Moll, Fred, 473–6
- Mulago Foundation, 758
- Nanostim, 790–3
- Narayana Hrudayalaya, 87
- National Collegiate Inventors and Innovators Alliance (NCIIA), 758
- national coverage determination (NCD), 353, 578–9
- National Health Service (NHS), 157, 167, 366, 396
- National Institute for Health and Care Excellence (NICE), 20, 167, 367, 581
- Nayak, Darshan, 82–3
- need
- blue sky, 100
 - categorizing, 100–1
 - criteria, 102–3, 235–6, 268, 274, 416
 - incremental, 100
 - insight, 103
 - mixed, 101
 - specification, 233–8, 268
 - validation, 101–2, 226–7
- need specification, 102
- need statement
- definition, 91
 - developing, 93–8
 - pitfalls, 95–8
 - scoping, 93–5
- needs exploration
- background research, 68–71
 - global considerations, 86–8
 - interviews, 77–8
 - knowing when to stop, 78–9
- observations, 71–6
- overview, 67–8
 - value, 81–6
- needs selection
- assigning ratings, 220–2
 - choosing factors, 217–21
 - combining values, 222–5
 - overview, 215–17
 - selecting needs, 224–6
 - specification, 233–8
 - validation, 226–7
- NeilMed, 653
- Neodyne Biosciences, 465
- NeoTract, Inc., 61, 499–502
- Newell, Bob, 710
- Niveus Medical, 423
- non-disclosure agreement (NDA), 311–12, 800
- Northwestern University, 98–9
- notice of allowance, 301
- notified bodies, 335
- null hypothesis, 513
- observation
- conducting, 72–4
 - documenting, 74–6
 - ethics, 76–7
 - preparing for, 68–71
- observer effect, 73
- Ocejo, Santiago, 504
- Oculeve, 412–13, 486–9
- OEC Medical Systems, 568–71
- office action (OA), 301, 460
- Office for Human Research Protections (OHRP), 516
- Office of Combination Products (OCP), 321, 536
- Office of Device Evaluation (ODE), 321
- Office of In Vitro Diagnostics and Radiological Health (OIR), 321, 323
- Office of Initial Patent Examination (OIPE), 301
- Office of Technology Licensing (OTL), 465, 806
- off-label use, 547
- One Medical, 394
- OneBreath, 445–7
- operating expenses (OpEx), 715
- option pool, 775
- Orthopaedic Implant Company, 615
- out-of-pocket payment, 156, 159, 360
- Palmaz, Julio, 251, 308
- Papanek, Julie, 236–8
- Papiernik, Antoine, 306–8
- partnering, 678–9
- Patent Cooperation Treat (PCT), 302–3
- patent litigation, 392
- patenting outside the US
- China, 304–5
 - India, 304
 - Patent Cooperation Treaty (PCT), 302–3
- PATH, 793
- pathophysiology, 121
- Patient Centered Outcomes Research Institute (PCORI), 585
- Perclose, 426
- Percusurge, Inc., 548
- Perkins, Rodney, 546, 740
- personal inventory
- mission, 51–4
 - relevance to alternate pathways, 787
 - strengths and weaknesses, 54
- Pfizer, 665, 678
- Phoenix Medical Systems, 376, 641–2
- Phoon, Justin, 277–8
- physiology, 119
- Pietzsch, Jan, 590–4
- Pinto, Moshe, 183, 463–4, 806–7
- pitch
- components, 728–33
 - considerations, 727–8
 - developing, 733–4
 - funding, 739–42
- Plain, Hank, 528, 546
- Popovits, Kim, 208, 620
- Porter's five forces, 195
- Practice Fusion, 397
- pre-amendment devices, 325
- predicate device, 538, 541
- preferred provider organizations (PPOs), 359
- preferred stock, 751
- premarket approval (PMA)
- cost, 331
 - meeting with FDA, 543
 - modular, 329
 - post-approval requirements, 543
 - product development protocol (PDP), 329
 - review process and timing, 329
 - strategies, 543
 - submission, 328–9
 - traditional, 328
- prevalence, 118
- pricing
- bundled, 621
 - differential, 620
 - establishing a baseline, 619
 - gainsharing, 621
 - link to reimbursement, 586
 - pay-for-performance, 622
 - value-based, 586, 619

Index

- prior art, 295, 302, 461
Privitera, Mary Bath, 79–81
professional societies, 65, 163, 579, 628
profitability, 722
proof-of-concept, 479, 482
Propeller Health, 653–5
protected health information (PHI), 77
prototyping
 in-house vs. outsourcing, 425–6
 models, 409–11
 testing, 417–25
 timing, 416
 tips, 429–30
prototyping guidelines
 choosing model, 409–11
 defining requirements, 415–16
 identifying functional blocks, 413–14
 identifying questions, 407–9
 understanding what is known, 414–15
proxy company analysis, 723
public relations strategy, 627–9
Pugh method for concept selection
 assigning scores and ranking concepts, 440
 confirming concepts and choose a baseline, 439
 identifying user and design requirements, 437
 iterative nature of, 436
 overview, 436
 weighting user and design requirements, 437
Pulmonx, 546
Qualcomm Life, 675–8
quality assurance (QA), 553
quality control (QC), 553
quality management system (QMS)
 CAPA, 559
 design controls, 556
 equipment and facility controls, 559
 implementing, 560–2
 ISO 13485, 562
 management controls, 555–6
 material controls, 560
 P&PC, 556–9
 QSIT, 567
 QSR, 552, 562
 QSR vs. ISO, 562–4
 records, documents, and change controls, 560
quality system audits, 567–8
R&D milestones, 481–2
R&D plan
 activities, 490–2
 engineering resources, 496–8
 link to strategy, 480–1
 personnel, 494–6
 timelines, 480–1
R&D technical challenges, 482–4
Radiology Partners, 388–91
Rainbow Medical, 756
Raje, Pulin, 82–3
Rao, Geetha, 332
Rapid Exchange, 803–5
reduction to practice, 289
referral patterns, 154
regulation in the US, *see* Food & Drug Administration (FDA)
regulation outside the US
 Australia, 336–7
 Brazil, 338
 Canada, 336
 China, 339–40
 Europe, 334–6
 India, 339
 Japan, 337
 Russia, 338–9
regulatory strategy
 510(k) strategies, 541
 510(k) vs. PMA, 538
 global strategies, 547–9
 IDE strategies, 537–8
 link to reimbursement, 535
 off-label use, 547
 premarket approval strategies, 541–3
reimbursement in the US
 background, 352
 coding, 352–3, 574–8
 coverage, 353, 578–81
 hospital inpatient reimbursement, 357–8
 hospital outpatient reimbursement, 357–8
 payment, 353–5, 581–5
 physician reimbursement, 355–7
 private payers, 358–60
 self-pay, 360
reimbursement outside the US
 China, 367–8
 France, 365–6
 Germany, 364–5
 India, 368–9
 overview, 363–4
 United Kingdom, 366–7
reimbursement strategy
 advocacy, 595–6
 competitors and proxies, 586
 design of clinical trials, 588
 developing, 585–6
 disseminating economic evidence, 594
 dossier, 594
 expanding reimbursement, 574–85
 parallel review, 580
 payer advisory boards, 596
 payer segmentation, 586–7
 payer value proposition, 588
 pricing, 586
 reimbursement support, 601
Relative Value Scale Update Committee (RUC), 583
relative value units (RVUs), 356, 583
Resource Based Relative Value System (RBRVS), 355
Respira Design, 504–5
Respironics, 79–81
Rock Health, 756
Rodriguez, Bill, 173–6
royalty-backed loans, 752
Rudy, Steve, 384–7
Russia, 18, 338–9
Sadler, Joel, 72
Sainz, Maria, 379
sales and distribution models
 choosing, 655–60
 direct, 642–51
 hybrid, 651–2
 indirect, 639–42
 overview, 636–9
 strategic considerations, 652–5
Satiety, 666
SciMed, 670
Scott, Randy, 206–8
self-pay, *see* out-of-pocket payment
SG&A expenses, 719–20
Sharma, Amit, 210–13, 261
Shelhigh Inc., 562
Shenasa, Jafar, 332
Sherman Act, 673
Sidow, Kevin, 381–3, 657
Simpirica Spine, 438, 441–2, 737–9
Simpson, Carl, 251, 442, 804
Simpson, John, 523–6, 803
simulated use testing, 423, 491
Singapore-Stanford Biodesign, 277
solution analysis
 clinical profile, 141–4
 economic profile, 144–5
 emerging profile, 145–6
 landscape, 146–9
 overview, 138–41
 utilization profile, 145

- solution bias, 97, 275
 solution gaps, 135, 147
 Spiracur, 185, 463–4, 806–7
 Sproxil, Inc., 762
 St. Francis Medical, 381–3, 656
 St. Goar, Fred, 426–9
 St. Jude Medical, 583, 758, 790–3
 Stack, Richard, 153, 183, 196–7
 staffing ratios, 706
 stakeholder analysis
 cycle of care, 153–6
 ethics, 178–9
 flow of money, 153, 156–8
 output, 177
 stakeholder interests
 facilities, 164–7
 government, 172–6
 patients, 159–62
 payers, 167–9
 physicians, 162–4
 Stanford-India Biodesign, 83, 86, 210, 227
 Stark Law, 622
 Starling, Bill, 196–7
 StartX, 756
 State Intellectual Property Office (SIPO), 304
 statistical power, 511, 513
 strategic focus
 acceptance criteria, 54–9
 ethics, 62–5
 external factors, 54
 global considerations, 61–2
 personal inventory, 51–4
 Stryker, 666, 673
 substantially equivalent (SE) determination, 327
 superseding need, 94
 Surmodics, 678
 SWOT analysis, 195–7
 Sympara Medical, 565–7
 Talmadge, Karen, 657–61
 Tenet, 652
 Teo, Pearline, 277–8
 term sheet, 775–6
 terminal value, 774
 testing continuum, 417, 479, 507
 Thapliyal, Hira, 484
 The Innovation Factory, 56, 756
 Thornton, Troy, 426–9
 Tilson, Alex, 777–81
 tissue testing, 424–5, 507
 trade secrets, 287
 trademark, 287
 TRIZ, 266
 US healthcare financing system, 157
 US Patent and Trademark Office (USPTO), 287, 459
 US Surgical, 668
 United Kingdom, 19, 366–7, 674–5
 University of Cincinnati, 79–81
 user testing, 417–20
 U-Systems, 628
 value, 1–4
 value analysis committee, 162, 636
 value estimate, 3, 196, 201, 612
 value exploration, 3, 81–6
 value proposition, 4
 developing, 611–18
 link to competitive advantage, 664–5
 payer-specific, 588–90
 physician-specific, 595
 selling, 644
 value signposts
 budget-based, 3, 85
 practice-based, 3, 82
 Van Sickle, David, 653–5
 Van Wert, Ryan, 420–3
 Van, Sue, 758–61
 Venkataswamy, Govindappa, 85
 venture debt, 752
 VentureHealth, 763–4
 Versant Ventures, 742–4
 VISX, 391–3
 VNUS Medical, 597–601
 Vortex Medical, 795–7
 Vynca, 420–3
 Wang, Frank, 420–3
 warrant, 773
 Wasden, Chris, 616
 WebMD, 397
 Welltok, 393
 Whitney, Rich, 388–91
 Will, Allan, 523–6
 Wilson Greatbatch, 678
 Wing Tech Inc., 590–4
 Winlo, Michael, 185–6, 194, 200
 Wohl, Barry, 505
 World Intellectual Property Organization (WIPO), 302
 Yock, Paul, 803–5
 Zang, Xiangwen, 86
 Zimmer, 666
 ZocDoc, 396
 Zoromski, Darrell, 606–11